Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine‐induced toxicity in an Asian population
Abstract Objective Dihydropyrimidine dehydrogenase (DPYD) genotype is closely associated with fluoropyrimidine (FP)‐induced toxicities in Caucasian population and European Medicines Agency now recommends DPYD genotype‐based FP dosing strategy. Patients and Methods The current study aimed to investig...
Main Authors: | Masashi Kanai, Takahisa Kawaguchi, Masahito Kotaka, Dai Manaka, Junichi Hasegawa, Akinori Takagane, Yoshinori Munemoto, Takeshi Kato, Tetsuya Eto, Tetsuo Touyama, Takanori Matsui, Katsunori Shinozaki, Shigemi Matsumoto, Tsunekazu Mizushima, Masaki Mori, Junichi Sakamoto, Atsushi Ohtsu, Takayuki Yoshino, Shigetoyo Saji, Fumihiko Matsuda |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5541 |
Similar Items
-
A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
by: Chi C. Tong, et al.
Published: (2018-07-01) -
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
by: Jonathan E. Knikman, et al.
Published: (2024-08-01) -
Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations
by: Jorge E. B. da Rocha, et al.
Published: (2021-03-01) -
Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines
by: Elena De Mattia, et al.
Published: (2024-12-01) -
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
by: Angela Wu, et al.
Published: (2023-09-01)